E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas

Journal of Pathology

Volumn 217, Issue 1, 2009, Pages 14-20

  De Meyer, T ^a   Bysmans, Itgw ^b   De Vijver, Kk Van ^b   Bekaert, S ^a   Oosting, J ^c   Criekinge, W Van ^a   Engeland, M Van ^b   Sieben, N L G ^b  

^a GHENT UNIVERSITY   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

E2F; Microarray expression analysis; Mutation; Progression; Serous borderline tumour; Serous ovarian carcinoma; TP53; Tumour of low malignant potential

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F3;

APOPTOSIS; ARTICLE; CANCER GRADING; CELL CYCLE REGULATION; CONTROLLED STUDY; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN TISSUE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

CELL CYCLE; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION PROFILING; GENES, P53; HUMANS; MUTATION; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 58449103236     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2452     Document Type: Article

References (34)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519- 2529.
2. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-1210.
3. Prat J. Surface epithelial-stromal tumors: Serous tumors. In Pathology of the Ovary, Prat J (ed). Saunders: Philadelphia, 2004;83-111.
4. Kurman RJ, Shih I. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-160.
5. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal Fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9.
6. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal Fallopian tube, endometrium, and colon. Clin Cancer Res 2005;11:6116-6126.
7. Scully RE, Young RH, Clement PB. Surface epithelial-stromal tumors; serous tumors. In Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament, Rosai J, Sobin LH (eds). Armed Forces Institute of Pathology: Washington, DC, 1998;51 -79.
8. Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol 2005;18:S33-S50.
9. Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 2002;26:1111-1128.
10. Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-1518.
11. Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-486.
12. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan FG, Houmadi R, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004;202:336-340.
13. Sieben NL, Oosting J, Flanagan AM, Prat J, Roemen GM, Kolkman-Uljee SM, et al. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 2005;23:7257-7264.
14. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-2984.
15. Salani R, Kurman RJ, Giuntoli R, Gardner G, Bristow R, Wang TL, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 2008;18:487-491.
16. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-3108.
17. Bracken AP, Ciro M, Cocito A, Helin K. E2F target genes: unraveling the biology. Trends Biochem Sci 2004;29:409-417.
18. Johnson DG, DeGregori J. Putting the oncogenic and tumor suppressive activities of E2F into context. Curr Mol Med 2006;6:731-738.
19. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005;65:10602-10612.
20. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, et al. Clinical relevance of E2F family members in ovarian cancer - an evaluation in a training set of 77 patients. Clin Cancer Res 2007;13:144-151.
21. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005;96:684-694.
22. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-525.
23. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;95:14863-14868.
24. Bieda M, Xu X, Singer MA, Green R, Farnham PJ. Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome. Genome Res 2006;16:595-605.
25. Ouellet V, Guyot MC, Le PC, Filali-Mouhim A, Lussier C, Tonin PN, et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 2006;119:599-607.
26. Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, et al. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res 2006;12:2404-2413.
27. Palazzo JP, Monzon F, Burke M, Hyslop T, Dunton C, Barusevicius A, et al. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors. Hum Pathol 2000;31:698-704.
28. Wang J, Shen WH, Jin YJ, Brandt-Rauf PW, Yin Y. A molecular link between E2F-1 and the MAP kinase cascade. J Biol Chem 2007;282:18521- 18531.
29. Cheung TH, Kwan YL, Hamady M, Liu X. Unraveling transcriptional control and cis-regulatory codes using the software suite GeneACT. Genome Biol 2006;7:R97.
30. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005;24:2810-2826.
31. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008;13:11-22.
32. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-6620.
33. Zhang HS, Postigo AA, Dean DC. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 1999;97:53-61.
34. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19:7-15.